Followers | 6 |
Posts | 28 |
Boards Moderated | 0 |
Alias Born | 09/18/2013 |
Saturday, May 30, 2015 9:46:24 AM
Newport Beach, California -- May 30, 2015 / (http://www.myprgenie.com) -- For Immediate Release For Further Information Contact:
May 29, 2015 Thomas Toland
949-698-8485 mobile
SURGLINE INTERNATIONAL, UPDATE on receiving its letter closing the investigation against the Company without enforcement action
WEST PALM BEACH, Fla. May 29, 2015 SurgLine International, Inc. (SGLN.PK)
SurgLine International, Inc. received a letter today from The United States Securities and Exchange Commission ("SEC") San Francisco Regional Office which closed its investigation against the company.
The letter stated that had not recommended enforcement against the company as of May 29 2015.
The CEO, Mr. Toland was pleased that the investigation had come to its conclusion without enforcement of any type at this date and that this brought to conclusion the long awaited chapter in the company's history commenced in the fall of 2012.
Mr. Toland was quoted as saying, "The Company fully cooperated with the Commission on this investigation and always held that it had not knowingly violated any terms or conditions that would have warranted this voluntary action in the fall of 2012."
Forward Looking Statements
This update release may contain forward-looking statements, including information about management’s view of future expectations, plans and prospects for SurgLine International, Inc. (the "Company"). In particular, when used in the preceding discussion, the words "predicts", "believes", "expects", "intends", "seeks", "estimates", "plans", "anticipates", and similar conditional expressions or future or conditional verbs such as "will", "may", "might", "should" "would" and "could" are intended to identify forward-looking statements. In addition, our representatives may from time to time make oral forward-looking statements. Any such statements, other than those of historical fact, about an action, event or development are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company’s management. Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in the relevant forward-looking statements as bine expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included herein are made only as of the date hereof. The company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date of the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that re not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under item, "Risk Factors" of the Company’s annual Report on Form 10-K for the year ended July 31, 2014 and in any of the Company’s other subsequent Securities and Exchange Commission filings.
Contact: Tom Toland, tom.toland2011@gmail.com, 949 698 8485
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM